Cannabis-based medicinal products: remote online prescribing of cannabis-based medicinal products

Page last updated: 12 May 2022

Wherever possible, we encourage consultations and decisions on prescribing to be made with the patient present. However, where this is not possible, prescribers should decide on an individual basis and after an appropriate risk assessment.

There is information in our guidance:

If we cannot be assured that the arrangements promote safe prescribing or we have evidence that remote consultations are not being carried out safely, we may take regulatory action. For example, we could impose conditions on your registration to prevent you from prescribing cannabis-based medicinal products remotely.